Wockhardt shares climb 2% after USFDA makes nil observation
In a regulatory filing, the company said no observations were made after the US drug regulator inspected its Bioequivalence centre.from Markets-Economic Times http://bit.ly/2IlYI0O
In a regulatory filing, the company said no observations were made after the US drug regulator inspected its Bioequivalence centre.from Markets-Economic Times http://bit.ly/2IlYI0O
Post a Comment